Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 76Neoplasms 16Prostatic Neoplasms, Castration-Resistant 14Neoplasm Metastasis 9Breast Neoplasms 9Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 5Metastatic Castration-Resistant Prostate Cancer 5Colorectal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3Bulbo-Spinal Atrophy, X-Linked 3mCRPC 2Recurrence 2Pancreatic Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castrate-Resistant Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Seizures 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × enzalutamide × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
49 enrolled 33 charts
BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡